Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6645223 | 0.89 | F2 (0.39) | F2NPC1RAB9ABACE1GRM4 | |
| SCHEMBL6648457 | 0.89 | F2 (0.40) | F2BACE1TRPV4MEN1KMT2A | |
| SCHEMBL6644199 | 0.88 | CYP3A4 (0.38) | F2NPC1RAB9ACYP3A4 | |
| SCHEMBL6645210 | 0.87 | F2 (0.37) | F2NPC1RAB9ABACE1TRPV4 | |
| SCHEMBL6646586 | 0.84 | SCN10A (0.47) | MEN1KMT2A | |
| SCHEMBL6644728 | 0.83 | SCN10A (0.40) | F2 | |
| SCHEMBL6796112 | 0.83 | MEN1 (0.41) | F2BACE1TRPV4MEN1KMT2A | |
| SCHEMBL6645327 | 0.81 | ALDH1A1 (0.43) | F2NPC1BACE1MEN1KMT2A | |
| SCHEMBL6645935 | 0.81 | KMT2A (0.42) | NPC1RAB9AKMT2ASORT1 | |
| SCHEMBL6645763 | 0.80 | NPC1 (0.33) | F2NPC1RAB9ASORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | F2 1415/4885NPC1 34/4885RAB9A 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.